Pharmacological management of transient synovitis.

Abstract:

:Synovitis is a painful and, occasionally, disabling disease. Patients with synovitis, especially new onset synovitis, should be referred to a rheumatologist urgently so that they can be assed and treated as quickly as possible. Clinical assessment and investigations are required to help differentiate between transient (< 3 months) and persistent (> 3 months) synovitis. This differentiation is important, as persistent synovitis can lead to joint damage and disability. Septic arthritis is a rheumatological emergency requiring immediate assessment and specific treatment. The earlier synovitis is treated, the more effective treatment is likely to be. If treated very early, there is potential to prevent the move from transient to persistent synovitis. Transient synovitis can be treated with painkillers, NSAIDs and/or corticosteroids, depending on severity. Persistent synovitis may also require disease-modifying drugs. Clinical indicators of persistence include symptom duration at first visit, early morning stiffness for > 1 h, arthritis in more than three joints, bilateral compression pain in metatarsophalangeal joints, rheumatoid factor positivity, anti-cyclic citrullinated peptide antibody positivity, erosions on hand or feet X-rays and a family history of rheumatoid arthritis. Disease-modifying drugs need to be considered early to achieve clinical remission before damage and disability occur. Despite emerging new treatments for synovitis, especially persistent synovitis, full clinical remission is still not achieved in most patients, and more research into disease processes and targeted therapies is required.

authors

Sokoll KB,Helliwell P

doi

10.1517/14656566.7.1.35

keywords:

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

35-46

issue

1

eissn

1465-6566

issn

1744-7666

journal_volume

7

pub_type

杂志文章,评审
  • Ziprasidone for maintenance treatment of bipolar I disorder in adults.

    abstract:INTRODUCTION:Antipsychotic drugs are increasingly used in the maintenance treatment of bipolar disorder. This review addresses the evidence supporting the use of one of these medications for this indication in order to place available data in perspective for the clinician. AREAS COVERED:The approval of ziprasidone for...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.2011.563237

    authors: Dubovsky SL,Dubovsky AN

    更新日期:2011-04-01 00:00:00

  • Advances in pharmacotherapy for hyperphosphatemia in renal disease.

    abstract:INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1092521

    authors: Spasovski G

    更新日期:2015-01-01 00:00:00

  • Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

    abstract:INTRODUCTION:Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia. AREAS COVERED:The effec...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.557359

    authors: Rizzo M,Corrado E,Patti AM,Rini GB,Mikhailidis DP

    更新日期:2011-03-01 00:00:00

  • Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

    abstract:BACKGROUND:Alzheimer's disease is thought to be caused by increased formations of neurotoxic amyloid beta (A beta) peptides, which give rise to the hallmark amyloid plaques. Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit. OBJECTIVE:This paper reviews the pharmacology and c...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903044982

    authors: Henley DB,May PC,Dean RA,Siemers ER

    更新日期:2009-07-01 00:00:00

  • 72nd Meeting of the American Heart Association. November 1999, Atlanta, Georgia, USA.

    abstract::The American Heart Association annual meeting must be one of the largest scientific gatherings, attracting over 30,000 delegates. The meeting at the end of last year was held in Atlanta, USA, the 2000 meeting will be in New Orleans, USA. The following highlights represent my own interests. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type:

    doi:10.1517/14656566.1.3.581

    authors: Lunnon MW

    更新日期:2000-03-01 00:00:00

  • Desvenlafaxine in the treatment of major depressive disorder.

    abstract::Desvenlafaxine (DESV) is a newer antidepressant, which inhibits serotonin-norepinephrine reuptake neurotransmission, similarly to venlafaxine, milnacipran and duloxetine. It was approved in February 2008 by the FDA for the treatment of major depressive disorder (MDD), based on well-controlled and adequately powered, l...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.636033

    authors: Pae CU

    更新日期:2011-12-01 00:00:00

  • The management of dermatomyositis: current treatment options.

    abstract::Dermatomyositis is traditionally classified as one of the idiopathic inflammatory myopathies. The traditional approach to the management of patients with dermatomyositis focuses predominantly on end points related to the systemic manifestations of this disorder, especially proximal muscle weakness resulting from myosi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.5.1083

    authors: Sontheimer RD

    更新日期:2004-05-01 00:00:00

  • Docetaxel in ovarian cancer.

    abstract::Docetaxel, a semisynthetic taxane, is a potent inhibitor of cell replication and, similar to paclitaxel, promotes in vitro assembly of stable microtubules and, therefore, prevents the depolymerisation process. Docetaxel has a higher affinity for the tubulin subunit and is associated with a 100-fold greater phosphoryla...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.15.2719

    authors: Escobar PF,Rose PG

    更新日期:2005-12-01 00:00:00

  • Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables.

    abstract:INTRODUCTION:Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of the central nervous system affecting both white matter and grey matter in the earliest phases of its course. The crucial role of neurodegeneration in disability progression in MS, regardless of white matter damage, has been confirm...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1434143

    authors: Pitteri M,Magliozzi R,Bajrami A,Camera V,Calabrese M

    更新日期:2018-03-01 00:00:00

  • Gout--what are the treatment options?

    abstract::There has been an increase in the incidence and prevalence of gout in the past several decades. A distinction needs to be made between the treatment of gout as an acute inflammatory disease and the lowering of the serum urate (SU) levels into a normal range. Treating acute gout attacks alone is not sufficient to preve...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902950742

    authors: Schlesinger N,Dalbeth N,Perez-Ruiz F

    更新日期:2009-06-01 00:00:00

  • Current concepts in the pharmacotherapy of benign prostatic hyperplasia.

    abstract::Benign prostatic hyperplasia is a major men's health issue, with approximately 80% of all men developing this condition within their lifetime. A variety of oral treatments is available, including alpha-adrenoceptor antagonists (alpha-blockers), 5alpha reductase inhibitors, aromatase inhibitors and phytotherapy. A larg...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.12.1727

    authors: Khastgir J,Arya M,Shergill IS,Kalsi JS,Minhas S,Mundy AR

    更新日期:2002-12-01 00:00:00

  • Pharmacological management of axial spondyloarthritis in adults.

    abstract::Introduction: Spondyloarthritis (SpA) refers to a group of disorders sharing common clinical, genetic and imaging characteristics. Axial (ax) SpA corresponds to a subgroup that mainly affects the axial skeleton, leading to inflammatory back pain and progressive radiographic changes of the sacroiliac joints and the spi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1617853

    authors: Toussirot E

    更新日期:2019-08-01 00:00:00

  • Apremilast as a treatment for psoriasis.

    abstract:INTRODUCTION:Psoriasis is a common skin disorder characterized by chronic inflammatory lesions that are frequently vexing for patients and difficult for physicians to treat. Although multiple therapeutic options are available, all have limitations. Topical preparations have issues with patient adherence, as compared to...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.699959

    authors: Shutty B,West C,Pellerin M,Feldman S

    更新日期:2012-08-01 00:00:00

  • Advances in pharmacotherapy of vestibular and ocular motor disorders.

    abstract:INTRODUCTION:Vertigo and dizziness are common chief complaints of vestibular and ocular motor disorders (lifetime prevalence 30%). Treatment relies on physical, pharmacological, psychological and rarely surgical approaches. Eight groups of drugs are currently used in vestibular and ocular motor disorders, namely anti-v...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1610386

    authors: Zwergal A,Strupp M,Brandt T

    更新日期:2019-07-01 00:00:00

  • A new ketoconazole topical gel formulation in seborrhoeic dermatitis: an updated review of the mechanism.

    abstract::Seborrhoeic dermatitis (SD) is a chronic, inflammatory skin disorder, affecting areas of the head and body where sebaceous glands are most prominent and active. The disorder commonly affects hair-bearing areas of the head, including the scalp. Involvement on the face is usually limited to the hairline, eyebrows, nasol...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.9.1365

    authors: Faergemann J,Borgers M,Degreef H

    更新日期:2007-06-01 00:00:00

  • Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.

    abstract:INTRODUCTION:Hyperphosphataemia is common in chronic kidney disease (CKD), particularly in the late stages and is associated with secondary hyperparathyroidism, abnormal bone mineralisation and increased cardiovascular morbidity/mortality. At present, there is a range of phosphate binders designed to keep serum phospha...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.928285

    authors: Locatelli F,Dimkovic N,Spasovski G

    更新日期:2014-07-01 00:00:00

  • Brimonidine tartrate for the treatment of glaucoma.

    abstract:INTRODUCTION:Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. Its use has been popularized due to its effects on aqueous suppression and uveoscleral outflow, as well as the suggestion of neuroprotection. Although available with alternative preservative vehicles,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1544241

    authors: Oh DJ,Chen JL,Vajaranant TS,Dikopf MS

    更新日期:2019-01-01 00:00:00

  • State-of-the-art pharmacotherapy for diabetic neuropathy.

    abstract:INTRODUCTION:The global epidemic of diabetes has led to an epidemic of diabetes complications. Diabetic neuropathy is the most common microvascular complication, of which diabetic peripheral neuropathy (DPN) and autonomic neuropathy (AN) are the most prevalent, affecting ~50% of patients. DPN results in pain with a poo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1812578

    authors: Azmi S,Alam U,Burgess J,Malik RA

    更新日期:2021-01-01 00:00:00

  • Baseline severity of depression predicts antidepressant drug response relative to escitalopram.

    abstract:OBJECTIVE:The intent of this pooled analysis was to determine the relationship between baseline depression symptom severity and treatment response for escitalopram compared to that for other pooled antidepressant medications (citalopram, duloxetine, fluoxetine, paroxetine, sertraline and venlafaxine). METHODS:Data wer...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560902849258

    authors: Kilts CD,Wade AG,Andersen HF,Schlaepfer TE

    更新日期:2009-04-01 00:00:00

  • Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

    abstract:INTRODUCTION:Sorafenib is a novel oral bis-aryl urea compound that has proven survival benefit in patients with advanced hepatocellular carcinoma (HCC), for which several therapies are currently available with unsatisfactory results. Sorafenib is the first compound to demonstrate a significant effect on survival in HCC...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.546346

    authors: Guan YS,He Q

    更新日期:2011-02-01 00:00:00

  • Tamoxifen and the female reproductive tract.

    abstract::The use of tamoxifen among women with breast cancer or at high risk of the disease has greatly expanded over the past several decades. Tamoxifen has a complex effect on the female reproductive tract and several tamoxifen-associated changes have been described among tamoxifen users. These include endometrial thickening...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.9.1399

    authors: Eltabbakh GH,Mount SL

    更新日期:2001-09-01 00:00:00

  • Meta-analysis of the efficacy of the fentanyl iontophoretic transdermal system versus intravenous patient-controlled analgesia in postoperative pain management.

    abstract:OBJECTIVE:This meta-analysis was conducted to analyze and compare the efficacy outcomes associated with the fentanyl iontophoretic transdermal system (ITS) and morphine intravenous (IV) patient-controlled analgesia (PCA) in the management of postoperative pain. RESEARCH DESIGN AND METHODS:This meta-analysis assessed t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,meta分析

    doi:10.1517/14656566.2015.1054279

    authors: Sinatra RS,Viscusi ER,Ding L,Danesi H,Jones JB,Grond S

    更新日期:2015-01-01 00:00:00

  • Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults.

    abstract:BACKGROUND:Prescription omega-3-acid ethyl esters (P-OM3) have been used as adjunctive therapy to statin drugs in patients with mixed hyperlipidemia. OBJECTIVE:To assess the effect of concomitant administration of 4 g P-OM3 on the steady-state pharmacokinetics of the maximum recommended daily dose of atorvastatin (80 ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14656560802233827

    authors: Di Spirito M,Morelli G,Doyle RT,Johnson J,McKenney J

    更新日期:2008-12-01 00:00:00

  • Treating myoclonic epilepsy in children: state-of-the-art.

    abstract:INTRODUCTION:Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.800045

    authors: Striano P,Belcastro V

    更新日期:2013-07-01 00:00:00

  • Therapeutic options for Acinetobacter baumannii infections.

    abstract::Acinetobacter baumannii is an important cause of nosocomial infections, mainly in patients in intensive care units. This microorganism, although with slight differences depending on the country, presents resistance to multiple antimicrobial agents, occasionally including resistance to colistin: hence, it can be consid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.4.587

    authors: Vila J,Pachón J

    更新日期:2008-03-01 00:00:00

  • Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy.

    abstract:IMPORTANCE OF THE FIELD:Statins are widely accepted as the drugs of choice for achieving increasingly stringent low-density lipoprotein cholesterol (LDL-C) goals for dyslipidemic patients. However, when making treatment decisions, outcomes data from clinical trials are of greater importance than LDL-C-lowering ability....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.516747

    authors: Weart CW,Hogan RJ

    更新日期:2011-01-01 00:00:00

  • Synthetic pharmacotherapy for lupus nephritis.

    abstract:INTRODUCTION:Lupus nephritis is a frequent complication and a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Area covered: The main characteristics and mechanisms of action of the synthetic drugs more frequently used in lupus nephritis are described. Possible strategies aime...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1276563

    authors: Moroni G,Ponticelli C

    更新日期:2017-02-01 00:00:00

  • Antipsychotic medication: effects on regulation of glucose and lipids.

    abstract::Since the introduction of chlorpromazine in the 1950s, antipsychotics have been used for the treatment of schizophrenia. The phenothiazines were followed by the butyrophenones, particularly haloperidol. With all the movement disorder side effects of these medications (extrapyramidal syndrome, akathisia, tardive dyskin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.10.1571

    authors: Kato MM,Goodnick PJ

    更新日期:2001-10-01 00:00:00

  • Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.

    abstract:INTRODUCTION:Treating acute myeloid leukemia (AML) in older adults remains daunting. The unique biology often renders conventional chemotherapies less effective. Accurately predicting the toxicities of treatment is another unresolved challenge. Treatment planning thus requires a good knowledge of the current trial data...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1465562

    authors: Michaelis LC,Klepin HD,Walter RB

    更新日期:2018-06-01 00:00:00

  • Memantine in the treatment of mild-to-moderate Alzheimer's disease.

    abstract::Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe Alzheimer's disease (AD). It is an NMDA receptor antagonist that works to prevent excitotoxicity and cell death, which are mediated by the excessive influx of calci...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.2.203

    authors: Cosman KM,Boyle LL,Porsteinsson AP

    更新日期:2007-02-01 00:00:00